The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization

被引:22
作者
Chen, Shu-Huey [2 ,3 ,4 ]
Yang, Shang-Hsien [2 ,3 ]
Chu, Sung-Chao [1 ]
Su, Yu-Chieh [3 ,5 ]
Chang, Chu-Yu [4 ]
Chiu, Ya-Wen [4 ]
Kao, Ruey-Ho [1 ,3 ]
Li, Dian-Kun [3 ,5 ]
Yang, Kuo-Liang [4 ]
Wang, Tso-Fu [1 ,3 ,4 ]
机构
[1] Tzu Chi Gen Hosp, Dept Hematol & Oncol, Hualien 970, Taiwan
[2] Tzu Chi Gen Hosp, Dept Pediat, Hualien 970, Taiwan
[3] Tzu Chi Univ, Coll Med, Dept Med, Hualien, Taiwan
[4] Buddhist Tzu Chi Stem Cells Ctr, Hualien, Taiwan
[5] Tzu Chi Gen Hosp, Dept Hematol & Oncol, Chiayi, Taiwan
关键词
Hematopoietic stem cells; Mobilization; Granulocyte colony-stimulating factor; White blood cell count; Side effects; HEALTHY DONORS; G-CSF; ANAPHYLACTOID REACTION; CENTER EXPERIENCE; FILGRASTIM; COLLECTION; LENOGRASTIM; APHERESIS; IMPACT; TERM;
D O I
10.1007/s12185-011-0844-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Granulocyte colony-stimulating factor (G-CSF) is now widely used for stem cell mobilization. We evaluated the role of post-G-CSF white blood cell (WBC) counts and donor factors in predicting adverse events and yields associated with mobilization. WBC counts were determined at baseline, after the third and the fifth dose of G-CSF in 476 healthy donors. Donors with WBC a parts per thousand yen 50 x 10(3)/mu L post the third dose of G-CSF experienced more fatigue, myalgia/arthralgia, and chills, but final post-G-CSF CD34(+) cell counts were similar. Although the final CD34(+) cell count was higher in donors with WBC a parts per thousand yen 50 x 10(3)/mu L post the fifth G-CSF, the incidence of side effects was similar. Females more frequently experienced headache, nausea/anorexia, vomiting, fever, and lower final CD34(+) cell count than did males. Donors with body mass index (BMI) a parts per thousand yen 25 showed higher incidences of sweat and insomnia as well as higher final CD34(+) cell counts. Donor receiving G-CSF a parts per thousand yen 10 mu g/kg tended to experience bone pain, headache and chills more frequently. Multivariate analysis indicated that female gender is an independent factor predictive of the occurrence of most side effects, except for ECOG > 1 and chills. Higher BMI was also an independent predictor for fatigue, myalgia/arthralgia, and sweat. Higher G-CSF dose was associated with bone pain, while the WBC count post the third G-CSF was associated with fatigue only. In addition, one donor in the study period did not complete the mobilization due to suspected anaphylactoid reaction. Observation for 1 h after the first injection of G-CSF is required to prevent complications from unpredictable side effects.
引用
收藏
页码:652 / 659
页数:8
相关论文
共 27 条
  • [1] Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor
    Adkins, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 812 - 813
  • [2] Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim
    Anderlini, P
    Przepiorka, D
    Seong, C
    Smith, TL
    Huh, YO
    Lauppe, J
    Champlin, R
    Korbling, M
    [J]. TRANSFUSION, 1997, 37 (05) : 507 - 512
  • [3] Anderlini P, 1997, BLOOD, V90, P903
  • [4] Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
    Anderlini, P
    Przepiorka, D
    Seong, D
    Miller, P
    Sundberg, J
    Lichtiger, B
    Norfleet, F
    Chan, KW
    Champlin, R
    Korbling, M
    [J]. TRANSFUSION, 1996, 36 (07) : 590 - 595
  • [5] Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim:: the M.D. Anderson Cancer Center experience
    Anderlini, P
    Donato, M
    Chan, KW
    Huh, YO
    Gee, AP
    Lauppe, MJ
    Champlin, RE
    Körbling, M
    [J]. TRANSFUSION, 1999, 39 (06) : 555 - 560
  • [6] Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection
    BatelCopel, L
    MommejaMarin, H
    Oudard, S
    Chauvenet, L
    PujadeLauraine, E
    Coupier, J
    Bernadou, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2428 - 2428
  • [7] THE EFFECTS OF DAILY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ADMINISTRATION ON NORMAL GRANULOCYTE DONORS UNDERGOING LEUKAPHERESIS
    BENSINGER, WI
    PRICE, TH
    DALE, DC
    APPELBAUM, FR
    CLIFT, R
    LILLEBY, K
    WILLIAMS, B
    STORB, R
    THOMAS, ED
    BUCKNER, CD
    [J]. BLOOD, 1993, 81 (07) : 1883 - 1888
  • [8] CONFER DL, 2007, HEMATOPOIETIC CELL D
  • [9] Administration of recombinant human granulocyte colony-stimulating factor to normal donors:: results of the Spanish National Donor Registry
    de la Rubia, J
    Martínez, C
    Solano, C
    Brunet, S
    Cascón, P
    Arrieta, R
    Alegre, A
    Bargay, J
    de Arriba, F
    Cañizo, C
    López, J
    Serrano, D
    Verdeguer, A
    Torrabadella, M
    Díaz, MA
    Insunza, A
    de la Serna, J
    Espigado, I
    Petit, J
    Martínez, M
    Benlloch, L
    Sanz, MA
    [J]. BONE MARROW TRANSPLANTATION, 1999, 24 (07) : 723 - 728
  • [10] Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors
    de la Rubia, J
    Arbona, C
    de Arriba, F
    del Cañizo, C
    Brunet, S
    Zamora, C
    Díaz, MA
    Bargay, J
    Petit, J
    de la Serna, J
    Insunza, A
    Arrieta, R
    Pascual, MJ
    Serrano, D
    Sanjuan, I
    Espigado, I
    Alegre, A
    Martínez, D
    Verdeguer, A
    Martínez, C
    Benlloch, L
    Sanz, MA
    [J]. TRANSFUSION, 2002, 42 (01) : 4 - 9